{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T23:03:20Z","timestamp":1769814200029,"version":"3.49.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NanoCarrier Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00280-017-3254-4","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T10:55:16Z","timestamp":1487674516000},"page":"569-578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK\/PD analysis"],"prefix":"10.1007","volume":"79","author":[{"given":"Toshihiko","family":"Doi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Hamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsunori","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6158-9459","authenticated-orcid":false,"given":"Atsuhiro","family":"Masada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"3254_CR1","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6602772","volume":"93","author":"H Uchino","year":"2005","unstructured":"Uchino H, Matsumura Y, Negishi T et al (2005) Cisplatin incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 93:678\u2013687","journal-title":"Br J Cancer"},{"key":"3254_CR2","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 46:6387\u20136392","journal-title":"Cancer Res"},{"key":"3254_CR3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2125.1998.00676.x","volume":"45","author":"A Sharma","year":"1998","unstructured":"Sharma A, Jusko W (1998) Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 45:229\u2013239","journal-title":"Br J Clin Pharmacol"},{"key":"3254_CR4","doi-asserted-by":"crossref","first-page":"e0142225","DOI":"10.1371\/journal.pone.0142225","volume":"10","author":"ZY Bhat","year":"2015","unstructured":"Bhat ZY, Cadnapaphornchai P, Ginsburg K, Sivagnanam M, Chopra S, Treadway CK (2015) Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: an observational cohort study. PLoS One 10:e0142225","journal-title":"PLoS One"},{"key":"3254_CR5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/030089160709300205","volume":"93","author":"T Marcello","year":"2007","unstructured":"Marcello T et al (2007) Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 93:138\u2013144","journal-title":"Tumori"},{"key":"3254_CR6","unstructured":"Package insert of Gemsar [JAPAN], vol.\u00a015, October 2013"},{"key":"3254_CR7","unstructured":"Package insert of Randa [JAPAN], August 2014"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3254-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T19:02:03Z","timestamp":1568833323000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3254-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["3254"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3254-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]}}}